PCSK9 and hyperlipidemia: PCSK9 inhibitors are a novel group of medicines, recently approved for management of hyperlipidemia, particularly with those individuals in whom LDL target is not met despite maximally tolerated doses of statins, patients with FH, or those at high risk of cardiovascular events.